본문 바로가기
KERD
논문KCI 등재

Chemopreventive Effect of Metformin on Gastric Cancer Development

Cheung Ka Shing|Chung Kit Lam|Leung Wai K.
거트앤리버 소화기연관학회협의회|2022.03|Gut and Liver|제16권 제2호|pp. 147-156|DOI 10.5009/gnl210132

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

Diabetes mellitusMetforminGut microbiotaHelicobacter pyloriChemoprevention

초록

Although Helicobacter pylori infection is the most important causative factor for gastric cancer (GC), H. pylori eradication alone does not completely eliminate the GC risk. In addition to H. pylori eradication, other risk factors for GC should be identified and targeted. Diabetes mellitus (DM) confers a 20% increased risk of GC, which could be mediated via several biological mechanisms including the stimulation of cell proliferation via hyperinsulinemia and increased insulingrowth factor production, the promotion of angiogenesis, and DNA damage. With a current global prevalence of 9.3% and a predicted rise to 10.2% by 2030, DM could contribute substantially to the burden of GC cases worldwide. Emerging evidence showed that metformin possesses chemopreventive effects via both direct (e.g., adenosine monophosphate-activated protein kinase activation and subsequent inhibition of the mammalian target of rapamycin pathway) and indirect (e.g., modulation of the interaction between tumor cells and their microenvironment and gut microbiota) pathways. A recent meta-analysis of observational studies showed that metformin use was associated with 24% lower GC risk. However, many available observational studies related to metformin effects suffered from biases including the failure to adjust for the H. pylori infection status and serial glycemic control and time-related biases. Future prospective studies addressing these pitfalls are needed.

Abstract

Although Helicobacter pylori infection is the most important causative factor for gastric cancer (GC), H. pylori eradication alone does not completely eliminate the GC risk. In addition to H. pylori eradication, other risk factors for GC should be identified and targeted. Diabetes mellitus (DM) confers a 20% increased risk of GC, which could be mediated via several biological mechanisms including the stimulation of cell proliferation via hyperinsulinemia and increased insulingrowth factor production, the promotion of angiogenesis, and DNA damage. With a current global prevalence of 9.3% and a predicted rise to 10.2% by 2030, DM could contribute substantially to the burden of GC cases worldwide. Emerging evidence showed that metformin possesses chemopreventive effects via both direct (e.g., adenosine monophosphate-activated protein kinase activation and subsequent inhibition of the mammalian target of rapamycin pathway) and indirect (e.g., modulation of the interaction between tumor cells and their microenvironment and gut microbiota) pathways. A recent meta-analysis of observational studies showed that metformin use was associated with 24% lower GC risk. However, many available observational studies related to metformin effects suffered from biases including the failure to adjust for the H. pylori infection status and serial glycemic control and time-related biases. Future prospective studies addressing these pitfalls are needed.

참고문헌 (102)

  1. Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185countries", CA Cancer J Clin, 68, pp.394~424 (2018)
  2. Fock KM, "Review article : the epidemiology and prevention of gastric cancer", Aliment Pharmacol Ther, 40, pp.250~260 (2014)
  3. Cervantes A, "Current questions for the treatment of advanced gastric cancer", Cancer Treat Rev, 39, pp.60~67 (2013)
  4. Van Cutsem E, "Gastric cancer", Lancet, 388, pp.2654~2664 (2016)
  5. Cavaleiro-Pinto M, "Helicobacter pylori infection and gastric cardia cancer : systematic review and meta-analysis", Cancer Causes Control, 22, pp.375~387 (2011)
  6. "Infection with Helicobacter pylori", IARC Monogr Eval Carcinog Risks Hum, 61, pp.177~240 (1994)
  7. Hooi JKY, "Global prevalence of Helicobacter pylori infection : systematic review and metaanalysis", Gastroenterology, 153, pp.420~429 (2017)
  8. International Agency for Research on Cancer, "Helicobacter pylori eradication as a strategy for preventing gastric cancer. IARC Working Group Reports. Volume 8" (2014), WHO Press
  9. Correa P, "The future of gastric cancer prevention", Gastric Cancer, 7, pp.9~16 (2004)
  10. Song H, "Incidence of gastric cancer among patients with gastric precancerous lesions : observational cohort study in a low risk Western population", BMJ, 351, pp.h3867~ (2015)
  11. Ford AC, "Helicobacter pylori eradication therapy to prevent gastric cancer : systematic review and meta-analysis", Gut, 69, pp.2113~2121 (2020)
  12. Wong BC, "Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China : a randomized controlled trial", JAMA, 291, pp.187~194 (2004)
  13. Chen HN, "Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia : evidence from a meta-analysis", Gastric Cancer, 19, pp.166~175 (2016)
  14. Pimanov SI, "Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer", J Gastroenterol Hepatol, 23, pp.1666~1671 (2008)
  15. Rokkas T, "The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis", Helicobacter, 12(Suppl 2), pp.32~38 (2007)
  16. Watari J, "Effect of eradication of Helicobacter pylori on the histology and cellular phenotype of gastric intestinal metaplasia", Clin Gastroenterol Hepatol, 6, pp.409~417 (2008)
  17. Hwang YJ, "Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication : a prospective study for up to 10 years", Aliment Pharmacol Ther, 47, pp.380~390 (2018)
  18. Li WQ, "Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups", J Natl Cancer Inst, 106, pp.dju116~ (2014)
  19. Cheung KS, "Risk of gastric cancer development after eradication of Helicobacter pylori", World J Gastrointest Oncol, 10, pp.115~123 (2018)
  20. Yoon JM, "Preexisting diabetes mellitus increases the risk of gastric cancer : a meta-analysis", World J Gastroenterol, 19, pp.936~945 (2013)
  21. Saeedi P, "Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045 : results from the International Diabetes Federation Diabetes Atlas, 9th edition", Diabetes Res Clin Pract, 157, pp.107843~ (2019)
  22. Pollak M, "Insulin and insulin-like growth factor signalling in neoplasia", Nat Rev Cancer, 8, pp.915~928 (2008)
  23. Tanigawa N, "Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma", J Clin Oncol, 15, pp.826~832 (1997)
  24. Lorenzi M, "High glucose induces DNA damage in cultured human endothelial cells", J Clin Invest, 77, pp.322~325 (1986)
  25. Dandona P, "Oxidative damage to DNA in diabetes mellitus", Lancet, 347, pp.444~445 (1996)
  26. Yang P, "Overweight, obesity and gastric cancer risk : results from a meta-analysis of cohort studies", Eur J Cancer, 45, pp.2867~2873 (2009)
  27. Wijnhoven BP, "Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group", Br J Surg, 86, pp.529~535 (1999)
  28. Bianchini F, "Overweight, obesity, and cancer risk", Lancet Oncol, 3, pp.565~574 (2002)
  29. Ikeda F, "Hyperglycemia increases risk of gastric cancer posed by Helicobacter pylori infection : a population-based cohort study", Gastroenterology, 136, pp.1234~1241 (2009)
  30. Kim TJ, "Diabetic biomarkers and the risk of proximal or distal gastric cancer", J Gastroenterol Hepatol, 31, pp.1705~1710 (2016)
  31. Miao ZF, "Diabetes mellitus and the risk of gastric cancer : a meta-analysis of cohort studies", Oncotarget, 8, pp.44881~44892 (2017)
  32. Chen YL, "Diabetes and risk of subsequent gastric cancer : a population-based cohort study in Taiwan", Gastric Cancer, 16, pp.389~396 (2013)
  33. Cheung KS, "Diabetes increases risk of gastric cancer after Helicobacter pylori eradication : a territory-wide study with propensity score analysis", Diabetes Care, 42, pp.1769~1775 (2019)
  34. Hamada H, "High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori : impacts of hiatal hernia and corpus gastritis", Aliment Pharmacol Ther, 14, pp.729~735 (2000)
  35. Upala S, "Association between Helicobacter pylori infection and metabolic syndrome : a systematic review and meta-analysis", J Dig Dis, 17, pp.433~440 (2016)
  36. Upala S, "Effects of Helicobacter pylori eradication on insulin resistance and metabolic parameters : a systematic review and metaanalysis", Eur J Gastroenterol Hepatol, 29, pp.153~159 (2017)
  37. Song X, "The efficacy of Helicobacter pylori eradication in diabetics and its effect on glycemic control : a systematic review and meta-analysis", Helicobacter, 26, pp.e12781~ (2021)
  38. Shimoyama S, "Diabetes mellitus carries a risk of gastric cancer : a meta-analysis", World J Gastroenterol, 19, pp.6902~6910 (2013)
  39. Sona MF, "Type 1 diabetes mellitus and risk of cancer : a meta-analysis of observational studies", Jpn J Clin Oncol, 48, pp.426~433 (2018)
  40. Tian T, "Diabetes mellitus and incidence and mortality of gastric cancer : a metaanalysis", Exp Clin Endocrinol Diabetes, 120, pp.217~223 (2012)
  41. Ge Z, "Diabetes mellitus and risk of gastric cancer : a systematic review and meta-analysis of observational studies", Eur J Gastroenterol Hepatol, 23, pp.1127~1135 (2011)
  42. Kuipers EJ, "Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication", N Engl J Med, 334, pp.1018~1022 (1996)
  43. Lundell L, "Systematic review : the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology", Aliment Pharmacol Ther, 42, pp.649~663 (2015)
  44. Cheung KS, "Long-term use of proton-pump inhibitors and risk of gastric cancer : a review of the current evidence", Therap Adv Gastroenterol, 12, pp.1756284819834511~ (2019)
  45. Jiang K, "Relationship between long-term use of proton pump inhibitors and risk of gastric cancer : a systematic analysis", J Gastroenterol Hepatol, 34, pp.1898~1905 (2019)
  46. Cheung KS, "Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori : a population-based study", Gut, 67, pp.28~35 (2018)
  47. Lee JK, "Proton pump inhibitor use and risk of gastric, colorectal, liver, and pancreatic cancers in a community-based population", Am J Gastroenterol, 115, pp.706~715 (2020)
  48. Moayyedi P, "Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin", Gastroenterology, 157, pp.682~691 (2019)
  49. Bosetti C, "Aspirin and the risk of colorectal and other digestive tract cancers : an updated meta-analysis through 2019", Ann Oncol, 31, pp.558~568 (2020)
  50. Cheung KS, "Modification of gastric cancer risk associated with proton pump inhibitors by aspirin after Helicobacter pylori eradication", Oncotarget, 9, pp.36891~36893 (2018)
  51. Keyomarsi K, "Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin", Cancer Res, 51, pp.3602~3609 (1991)
  52. Dimitroulakos J, "Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas", Neoplasia, 4, pp.337~346 (2002)
  53. Park HJ, "3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA", Circ Res, 91, pp.143~150 (2002)
  54. Kusama T, "3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis", Gastroenterology, 122, pp.308~317 (2002)
  55. Shaheen NJ, "Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs", Cancer, 94, pp.950~963 (2002)
  56. Cuzick J, "Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention : an international consensus statement", Lancet Oncol, 10, pp.501~507 (2009)
  57. Yamamoto Y, "Sulindac inhibits activation of the NF-kappaB pathway", J Biol Chem, 274, pp.27307~27314 (1999)
  58. Patrignani P, "Aspirin and cancer", J Am Coll Cardiol, 68, pp.967~976 (2016)
  59. Singh PP, "Statins are associated with reduced risk of gastric cancer : a systematic review and meta-analysis", Ann Oncol, 24, pp.1721~1730 (2013)
  60. Cheung KS, "Aspirin and risk of gastric cancer after Helicobacter pylori eradication : a territory-wide study", J Natl Cancer Inst, 110, pp.743~749 (2018)
  61. Cheung KS, "Statins were associated with a reduced gastric cancer risk in patients with eradicated Helicobacter pylori infection : a territory-wide propensity score matched study", Cancer Epidemiol Biomarkers Prev, 29, pp.493~499 (2020)
  62. Sung JJ, "Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions", Am J Pathol, 157, pp.729~735 (2000)
  63. Leung WK, "Effects of long-term rofecoxib on gastric intestinal metaplasia : results of a randomized controlled trial", Clin Cancer Res, 12, pp.4766~4772 (2006)
  64. Wong BC, "Effects of selective COX-2inhibitor and Helicobacter pylori eradication on precancerous gastric lesions", Gut, 61, pp.812~818 (2012)
  65. Li B, "Nonaspirin nonsteroidal anti-inflammatory drugs and gastric cancer risk after Helicobacter pylori eradication : a territory-wide study", Cancer, 127, pp.1805~1815 (2021)
  66. Cerda-Opazo P, "Inverse expression of survivin and reprimo correlates with poor patient prognosis in gastric cancer", Oncotarget, 9, pp.12853~12867 (2018)
  67. Yusufu A, "Expression and clinical correlation of Survivin and PTEN in gastric cancer patients", Oncol Lett, 20, pp.297~ (2020)
  68. Jalving M, "Metformin : taking away the candy for cancer", Eur J Cancer, 46, pp.2369~2380 (2010)
  69. Han G, "AMPK", mTORmediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell, 2015, pp.16, 77~87
  70. Kato K, "The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo", Mol Cancer Ther, 11, pp.549~560 (2012)
  71. Chia NY, "Regulatory crosstalk between lineage-survival oncogenes KLF5, GATA4 and GATA6cooperatively promotes gastric cancer development", Gut, 64, pp.707~719 (2015)
  72. Chiurillo MA, "Role of the Wnt", β-catenin pathway in gastric cancer : an in-depth literature review, 2015, pp.5, 84~102
  73. Valaee S, "Metformin inhibits gastric cancer cells metastatic traits through suppression of epithelial-mesenchymal transition in a glucose-independent manner", PLoS One, 12, pp.e0174486~ (2017)
  74. Jun KH, "Clinicopathological significance of N-cadherin and VEGF in advanced gastric cancer brain metastasis and the effects of metformin in preclinical models", Oncol Rep, 34, pp.2047~2053 (2015)
  75. Huang D, "Negative regulation of Bmi-1 by AMPK and implication in cancer progression", Oncotarget, 7, pp.6188~6200 (2016)
  76. Song Z, "Metformin suppresses the expression of Sonic hedgehog in gastric cancer cells", Mol Med Rep, 15, pp.1909~1915 (2017)
  77. Courtois S, "Metformin targets gastric cancer stem cells", Eur J Cancer, 84, pp.193~201 (2017)
  78. Heckman-Stoddard BM, "Repurposing metformin for the prevention of cancer and cancer recurrence", Diabetologia, 60, pp.1639~1647 (2017)
  79. Franciosi M, "Metformin therapy and risk of cancer in patients with type 2 diabetes : systematic review", PLoS One, 8, pp.e71583~ (2013)
  80. Courtois S, "The therapeutic potential of metformin in gastric cancer", Gastric Cancer, 22, pp.653~662 (2019)
  81. Chen G, "Metformin suppresses gastric cancer progression through calmodulin‑like protein 3 secreted from tumor‑associated fibroblasts", Oncol Rep, 41, pp.405~414 (2019)
  82. Courtois S, "Metformin can inhibit Helicobacter pylori growth", Future Microbiol, 13, pp.1575~1583 (2018)
  83. Eikawa S, "Immune-mediated antitumor effect by type 2 diabetes drug, metformin", Proc Natl Acad Sci U S A, 112, pp.1809~1814 (2015)
  84. Wu H, "Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug", Nat Med, 23, pp.850~858 (2017)
  85. Wang YB, "Immortal time bias exaggerates the effect of metformin on the risk of gastric cancer : a meta-analysis", Pharmacol Res, 165, pp.105425~ (2021)
  86. Shuai Y, "The effect of metformin on gastric cancer in patients with type 2 diabetes : a systematic review and meta-analysis", Clin Transl Oncol, 22, pp.1580~1590 (2020)
  87. Zhou XL, "Association between metformin and the risk of gastric cancer in patients with type 2 diabetes mellitus : a meta-analysis of cohort studies", Oncotarget, 8, pp.55622~55631 (2017)
  88. Li P, "Metformin use and its effect on gastric cancer in patients with type 2 diabetes : a systematic review of observational studies", Oncol Lett, 15, pp.1191~1199 (2018)
  89. Lee MS, "Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese : a representative population prospective cohort study of 800, 000 individuals", BMC Cancer, 11, pp.20~ (2011)
  90. Home PD, "Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT(A Diabetes Outcome Progression Trial)and RECORD(Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes)clinical trials", Diabetologia, 53, pp.1838~1845 (2010)
  91. Ruiter R, "Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives : results from a large populationbased follow-up study", Diabetes Care, 35, pp.119~124 (2012)
  92. Kim YI, "Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment : a nationwide cohort study", Aliment Pharmacol Ther, 39, pp.854~863 (2014)
  93. Hsieh MC, "The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese", Exp Diabetes Res, 2012, pp.413782~ (2012)
  94. Tseng CH, "Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus", Aging(Albany NY), 8, pp.1636~1649 (2016)
  95. Valent F, "Diabetes mellitus and cancer of the digestive organs : an Italian population-based cohort study", J Diabetes Complications, 29, pp.1056~1061 (2015)
  96. Cheung KS, "Metformin use and gastric cancer risk in diabetic patients after Helicobacter pylori eradication", J Natl Cancer Inst, 111, pp.484~489 (2019)
  97. Cheung KS, "Application of Big Data analysis in gastrointestinal research", World J Gastroenterol, 25, pp.2990~3008 (2019)
  98. Yamagata H, "Impact of fasting plasma glucose levels on gastric cancer incidence in a general Japanese population : the Hisayama study", Diabetes Care, 28, pp.789~794 (2005)
  99. Suissa S, "Metformin and the risk of cancer : time-related biases in observational studies", Diabetes Care, 35, pp.2665~2673 (2012)
  100. Targownik LE, "Understanding and avoiding immortal-time bias in gastrointestinal observational research", Am J Gastroenterol, 110, pp.1647~1650 (2015)
  101. Suissa S, "Time-window bias in case-control studies : statins and lung cancer", Epidemiology, 22, pp.228~231 (2011)
  102. Cheung KS, "Response to Khosrow-Khavar, Kurteva, and Douros", J Natl Cancer Inst, 111, pp.1109~ (2019)

관련 논문AI추천

Metformin Use May Increase Risk of Pancreatic Cancer in Diabetic Women: An Analysis of the Korean National Health Insurance Service-National Health Screening Cohort DatabaseHee-Taik Kang, Joungyoun Kim, Yoon-Jong Bae대한가정의학회 · Korean Journal of Family Medicine2022 · 제43권 제5호Effects of early medication treatment and metformin use for cancer prevention in diabetes patients: a nationwide sample cohort study using extended landmark-time analysis서화정, 오현숙한국역학회 · Epidemiology and Health2021 · 제43권 Diabetes Medication Use in Association with Survival among Patients of Breast, Colorectal, Lung, or Gastric CancerGong Yang, Harvey Murff, Honglan Li, Liling Xu, Michelle L. Baglia, Mingrong You, Tao Zheng, Wei Zheng, Xiao-Ou Shu, Yong-Bing Xiang, Yong Cui, Yu-Tang Gao대한암학회 · Cancer Research and Treatment2019 · 제51권 제2호Current evidence of effects of Helicobacter pylori eradication on prevention of gastric cancer최일주대한내과학회 · The Korean Journal of Internal Medicine2013 · 제28권 제5호The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy김태용, 김태유, 방영주, 오도연, 이경훈, 임석아, 최연악, 한세원대한암학회 · Cancer Research and Treatment2016 · 제48권 제1호Rethinking about Metformin: Promising PotentialsKyunam Kim대한가정의학회 · Korean Journal of Family Medicine2024 · 제45권 제5호

이 간행물의 다른 논문 (18건)

Management of Antithrombotics before Endoscopy-Balancing the RisksKim Byung-Wook, 김준성pp. 141-142Diagnostic Performance of a Comprehensive Risk Model for Posthepatectomy Liver FailureChung Yong Eunpp. 143-144Biliary Complications after Living Donor Liver Transplantation Differ from Those after Deceased Donor Liver TransplantationJang Sung Ill, Lee Dong Kipp. 145-146Long-term Disease Course of Crohn’s Disease: Changes in Disease Location, Phenotype, Activities, and Predictive FactorsCho Choong Wui, 문성경, 이창균, 유명원, Oh Chi Hyukpp. 157-170Multidimensional Biomarker Analysis Including Mitochondrial Stress Indicators for Nonalcoholic Fatty Liver DiseasePark Kyu-Sang, Chang Jae Seung, Kim Moon Young, Chang Eunha, Kong In Deok, Baik Soon Koopp. 171-189
원문 보기